Ibere Pharmaceuticals (NYSE:IBER – Get Rating)’s share price was up 0.1% during mid-day trading on Friday . The stock traded as high as $10.01 and last traded at $10.00. Approximately 7,937 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 47,495 shares. The stock had previously closed at $9.99.
Ibere Pharmaceuticals Stock Up 0.1 %
The company has a 50 day moving average of $9.93 and a two-hundred day moving average of $9.86.
Hedge Funds Weigh In On Ibere Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in shares of Ibere Pharmaceuticals in the 3rd quarter valued at about $250,000. Mizuho Securities USA LLC bought a new stake in Ibere Pharmaceuticals during the third quarter worth about $398,000. Cubist Systematic Strategies LLC acquired a new position in Ibere Pharmaceuticals during the 3rd quarter worth about $698,000. Saba Capital Management L.P. bought a new position in Ibere Pharmaceuticals in the 1st quarter valued at $785,000. Finally, Bank of America Corp DE acquired a new position in Ibere Pharmaceuticals in the first quarter valued at approximately $3,139,000. Institutional investors and hedge funds own 71.43% of the company’s stock.
About Ibere Pharmaceuticals
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
- Get a free copy of the StockNews.com research report on Ibere Pharmaceuticals (IBER)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Ibere Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ibere Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.